{"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"306"}],"units":"Participants"}],"groups":[{"description":"Patients receive melphalan, prednisone and thalidomide induction plus thalidomide maintenance (MPT-T).\n\nINDUCTION THERAPY: Patients receive melphalan PO and prednisone PO daily on days 1-4, and thalidomide PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive thalidomide PO daily and continue in the absence of disease progression.\n\nmelphalan: Given PO\n\nprednisone: Given PO\n\nthalidomide: Given PO","id":"BG000","title":"Arm I (MPT-T)"},{"description":"Patients receive lower-dose melphalan, prednisone and lenalidomide (Revlimid®) induction plus lenalidomide maintenance (mPR-R).\n\nINDUCTION THERAPY: Patients receive melphalan PO and prednisone PO daily on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression.\n\nmelphalan: Given PO\n\nprednisone: Given PO\n\nlenalidomide: Given PO","id":"BG001","title":"Arm II (mPR-R)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"291"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"139"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"167"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"81"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"128"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"95"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"Unknown/Missing"}],"description":"The staging criteria for International Staging System:\n\nStage I: Serum β2 microglobulin \\<3.5 mg/L, Serum albumin ≥ 3.5 g/dL Stage II: Not I or III Stage III: Serum β2 microglobulin \\>5.5 mg/L","paramType":"NUMBER","title":"International Staging System (ISS)","unitOfMeasure":"participants"}]}